National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-14: The Prospects for Immunizing Against Salmonella typhi." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
320
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

PATHOGEN DESCRIPTION

Salmonella typhi, an obligate intracellular pathogen, is the cause of typhoid fever. The organism is a gram-negative, nonsporing bacillus, actively motile with numerous long peritrichous flagellae. Other salmonellae, S.paratyphi A and B, cause paratyphoid fever, which is similar to typhoid fever but usually a milder disease clinically. These organisms can be differentiated based on their cultural characteristics. S. typhi and S. paratyphi have a strong host specificity for man and do not naturally infect animals. In most countries in which these diseases have been studied, the ratio of disease caused by S. typhi to that caused by S. paratyphi is about 10 to 1. (For further information on S.typhi, see Hornick, 1982, 1985.)

HOST IMMUNE RESPONSE

Infection with S. typhi confers some immunity, but second illnesses can occur following reexposure. It appears that immunity can be overwhelmed by the ingestion of a large number of S. typhi, as was suggested by studies in which volunteers with previously documented typhoid fever ingested 105 S. typhi and had a clinical attack rate similar to that of a control group.

Several specific antibody responses have been demonstrated after typhoid fever. However, there is no evidence that these responses to O, H, and Vi antigens are protective against infection or illness. It is likely that secretory IgA is also produced in the small intestine, but this has not been well documented.

Animal models indicate that the cellular immune response probably is of primary importance in the protection against typhoid fever. Host defense relies on macrophage microbicidal mechanisms to kill phagocytosed bacteria. Enhancement of macrophage function is directed by specifically committed activated T-lymphocytes and controlled by a family of effector and regulatory T-cells. Current knowledge about immunity to S. typhi in humans does not permit more than general speculation about the way in which cell-mediated immunity is stimulated by either prior disease or a vaccine to prevent acute typhoid fever and its complications, or the development of the chronic carrier state (Germanier, 1984; Hornick, 1982, 1985; Levine et al., 1983).

DISTRIBUTION OF DISEASE

Geographic Distribution

Typhoid fever has worldwide distribution, but is especially prevalent in less-developed countries. Areas with environmental conditions conducive to the spread of the disease or with populations with a high prevalence of biliary tract disease and chronic carriage of S. typhi have higher rates of the disease (Germanier, 1984).

Page
320
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)